InSilico Medicine Launches Hong Kong IPO

MT Newswires Live

12/18

InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.

The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.

The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.

The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.

InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.

Morgan Stanley, China International Capital Corp., GF Securities (Hong Kong), BNP Paribas Securities (Asia), Sinolink Securities (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592928946"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592928946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592928946?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592928946","market":"us","top_or_hot":-1,"title":"InSilico Medicine Launches Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.</p><p>The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.</p><p>The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.</p><p>The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.</p><p>InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.</p><p>Morgan Stanley, China International Capital Corp., <a href=\"https://laohu8.com/S/GFSEF\">GF Securities</a> (Hong Kong), BNP Paribas Securities (Asia), <a href=\"https://laohu8.com/S/600109\">Sinolink Securities</a> (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InSilico Medicine Launches Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInSilico Medicine Launches Hong Kong IPO\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-18 10:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.</p><p>The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.</p><p>The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.</p><p>The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.</p><p>InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.</p><p>Morgan Stanley, China International Capital Corp., <a href=\"https://laohu8.com/S/GFSEF\">GF Securities</a> (Hong Kong), BNP Paribas Securities (Asia), <a href=\"https://laohu8.com/S/600109\">Sinolink Securities</a> (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592928946","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592928946","pubTimestamp":1766023317,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InSilico Medicine  launched its initial public offering in Hong Kong to raise HK$2.28 billion.The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.Morgan Stanley, China International Capital Corp., GF Securities , BNP Paribas Securities , Sinolink Securities , and BOCI Asia are the joint bookrunners of the IPO.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"InSilico Medicine启动香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":0.9},"content_text":"InSilico Medicine (HKG:3696) launched its initial public offering in Hong Kong to raise HK$2.28 billion.The Boston-based biotechnology firm is offering nearly 94.7 million shares at an indicative price of HK$24.05 apiece, according to a bourse filing Thursday.The issuer expects to disclose allocations on Dec. 29 and begin trading on the Hong Kong bourse on Dec. 30.The company secured 16 cornerstone investors who committed to buying $115 million worth of IPO shares.InSilico Medicine will use the IPO proceeds to fund clinical research and development of its drug candidates, develop generative artificial intelligence models, expand its automated lab, and for working capital.Morgan Stanley, China International Capital Corp., GF Securities (Hong Kong), BNP Paribas Securities (Asia), Sinolink Securities (Hong Kong), and BOCI Asia are the joint bookrunners of the IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}